Cynata raises $1.5 million ahead of Phase 3 osteoarthritis and Phase 2 aGvHD readouts
May 04, 2026
Cynata raised $1.5 million through a placement at $0.25 a share ahead of Phase 3 osteoarthritis and Phase 2 aGvHD trial readouts due in May and June 2026. Its aGvHD study has completed the 100-day primary evaluation period for all 65 participants.